|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.32 CHF | +1.97% |
|
+4.94% | +8.78% |
| May. 10 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
| May. 10 | Novartis Gets FDA Breakthrough Therapy Designation for Scemblix | DJ |
By Mauro Orru
Novartis AG said late Tuesday that the U.S. Food and Drug Administration has extended its review of the supplemental biologics license application for ofatumumab.
The Swiss drug giant said regulatory action is expected in the U.S. in September 2020, anticipating approval for the targeted B-cell therapy for patients with relapsing multiple sclerosis in Europe by the second quarter of 2021.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
| 1st Jan change | Capi. | |
|---|---|---|
| +8.78% | 208B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| -7.93% | 200B | |
| +7.68% | 166B | |
| -2.71% | 159B |
NOVARTIS AG 
